Phase 2Terminated
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Identify the Optimal Weekly Oral Dose of Ecnoglutide (VRB-101) for Maintaining Body Weight in Participants With Obesity or Overweight Who Have Weight-Related Comorbidities
- Sponsor
- Verdiva Bio Dev Limited (Industry)
- Enrolment
- 8 enrolled
- Conditions
- Obesity; Overweight; Weight Maintenance
- Interventions
- VRB-101; Placebo
- Ages
- adults, older adults
- Registry
- NCT07553299
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
Primary outcomes
- To identify the dose of VRB-101 for weight maintenance
History
Last registry update
Primary completion
Started
Registered